Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Sequential, two-period study to assess the pharmacokinetics, safety & tolerability of single and multiple oral doses of AFQ056 in patients with FXS (Fragile X syndrome) aged 5-11 years (Cohort 1) and 3-4 years (Cohort 2)

    Summary
    EudraCT number
    2011-004867-65
    Trial protocol
    Outside EU/EEA   ES  
    Global end of trial date
    16 Oct 2013

    Results information
    Results version number
    v1(current)
    This version publication date
    13 Jul 2016
    First version publication date
    23 Jul 2015
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CAFQ056B2154
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01482143
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Novartis Pharma AG
    Sponsor organisation address
    CH-4002, Basel, Switzerland,
    Public contact
    Clinical Disclosure Office, Novartis Pharma AG, +41 613241111,
    Scientific contact
    Clinical Disclosure Office, Novartis Pharma AG, +41 613241111,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-001003-PIP01-10
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    16 Oct 2013
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    16 Oct 2013
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective was to assess the pharmacokinetics of single and multiple oral AFQ056 doses in patients with Fragile X Syndrome (FXS) aged 5-11 years (cohort 1) and 3-4 years if included in the study (cohort 2)
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    23 Mar 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 4
    Country: Number of subjects enrolled
    United States: 17
    Worldwide total number of subjects
    21
    EEA total number of subjects
    4
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    21
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    A total of twelve patients with FXS aged 5-11 years inclusive were enrolled to cohort 1. As the results from cohort 1 allowed the study to progress to cohort 2, an additional nine patients aged 3-4 years inclusive were recruited.

    Pre-assignment
    Screening details
    Patient selection was established by checking through all inclusion/exclusion criteria at screening and first baseline visit.

    Period 1
    Period 1 title
    Treatment Period 1
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Cohort 1-Treatment Period 1
    Arm description
    Cohort 1 included children in the age group of 5 to 11 years
    Arm type
    Experimental

    Investigational medicinal product name
    AFQ056
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Single dose of 15 mg (10 mg/ml oral suspension in water) administered to the patients via a syringe. Saccharin sodium as a sweetener and tutti-frutti aroma were added to improve the taste.

    Arm title
    Cohort 2-Treatment Period 1
    Arm description
    Cohort 2 included children in the age group of 3 to 4 years
    Arm type
    Experimental

    Investigational medicinal product name
    AFQ056
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Single dose of 15 mg (10 mg/ml oral suspension in water) administered to the patients via a syringe. Saccharin sodium as a sweetener and tutti-frutti aroma were added to improve the taste.

    Number of subjects in period 1
    Cohort 1-Treatment Period 1 Cohort 2-Treatment Period 1
    Started
    12
    9
    Completed
    12
    9
    Period 2
    Period 2 title
    Treatment Period 2
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Cohort 1-Treatment Period 2
    Arm description
    Cohort 1 included children in the age group of 5 to 11 years
    Arm type
    Experimental

    Investigational medicinal product name
    AFQ056
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Day 1 to Day 7: multiple doses twice daily; 50 mg, 100 mg, or 1.25 mg/kg (10 mg/ml oral suspension in water) administered to the patients via a syringe. Doses were individualized based on the results obtained in period 1. Saccharin sodium as a sweetener and tutti-frutti aroma were added to improve the taste. If the dose normalized Cmax and the dose normalized AUCinf from the 15 mg dose of period 1 for the individuals did not exceed the 90th percentile of the over all population (adults and adolescents), then the exposures from the 15 mg dose in period 1 guided the selection of doses for period 2 for each individual. If the dose normalized Cmax and the dose normalized AUCinf of the subjects from the 15 mg dose of period 1 fell above the 90th percentile, then mg/kg dosing was implemented instead of fixed dosing in period 2 for these subjects.

    Arm title
    Cohort 2-Treatment Period 2
    Arm description
    Cohort 2 included children in the age group of 3 to 4 years
    Arm type
    Experimental

    Investigational medicinal product name
    AFQ056
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Day 1 to Day 8: multiple doses twice daily (b.i.d.) 50 mg, 100 mg, or 1.25 mg/kg (10 mg/ml oral suspension in water) administered to the patients via a syringe. Doses were individualized and up-titrated based on the results obtained in period 1. Up-titration as follows: starting dose of 25 mg b.i.d. and daily increments of 25 mg up to the assigned target dose. If the dose normalized Cmax and the dose normalized AUCinf from the 15 mg dose of period 1 for the individuals did not exceed the 90th percentile of the over all population (adults and adolescents), then the exposures from the 15 mg dose in period 1 guided the selection of doses for period 2 for each individual. If the dose normalized Cmax and the dose normalized AUCinf of the subjects from the 15 mg dose of period 1 fell above the 90th percentile, then mg/kg dosing was implemented instead of fixed dosing in period 2 for these subjects.

    Number of subjects in period 2
    Cohort 1-Treatment Period 2 Cohort 2-Treatment Period 2
    Started
    12
    9
    Completed
    12
    9

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Cohort 1-Treatment Period 1
    Reporting group description
    Cohort 1 included children in the age group of 5 to 11 years

    Reporting group title
    Cohort 2-Treatment Period 1
    Reporting group description
    Cohort 2 included children in the age group of 3 to 4 years

    Reporting group values
    Cohort 1-Treatment Period 1 Cohort 2-Treatment Period 1 Total
    Number of subjects
    12 9 21
    Age categorical
    Units: Subjects
        Children (2-11 years)
    12 9 21
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    7.7 ( 2.15 ) 3.9 ( 0.33 ) -
    Gender categorical
    Units: Subjects
        Female
    1 1 2
        Male
    11 8 19

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Cohort 1-Treatment Period 1
    Reporting group description
    Cohort 1 included children in the age group of 5 to 11 years

    Reporting group title
    Cohort 2-Treatment Period 1
    Reporting group description
    Cohort 2 included children in the age group of 3 to 4 years
    Reporting group title
    Cohort 1-Treatment Period 2
    Reporting group description
    Cohort 1 included children in the age group of 5 to 11 years

    Reporting group title
    Cohort 2-Treatment Period 2
    Reporting group description
    Cohort 2 included children in the age group of 3 to 4 years

    Primary: Dose-normalized Maximum Observed Plasma Concentration (Cmax) After a Single Dose of AFQ056

    Close Top of page
    End point title
    Dose-normalized Maximum Observed Plasma Concentration (Cmax) After a Single Dose of AFQ056 [1]
    End point description
    The observed maximum plasma concentration following AFQ056 administration [mass / volume] normalized for dose
    End point type
    Primary
    End point timeframe
    Over 24 hours post dose on Day 1 of Treatment Period 1
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was planned for this primary outcome measure.
    End point values
    Cohort 1-Treatment Period 1 Cohort 2-Treatment Period 1
    Number of subjects analysed
    12
    9
    Units: ng/mL/mg
        geometric mean (confidence interval 90%)
    2.88 (2.09 to 3.97)
    4.67 (3.71 to 5.88)
    No statistical analyses for this end point

    Primary: Dose-normalized Area Under The Plasma Concentration-Time Curve (AUC) From Time 0 to 12 Hours Post Dose (AUC0-12h) After a Single Dose of AFQ056

    Close Top of page
    End point title
    Dose-normalized Area Under The Plasma Concentration-Time Curve (AUC) From Time 0 to 12 Hours Post Dose (AUC0-12h) After a Single Dose of AFQ056 [2]
    End point description
    The AUC from time 0 to t= 12 hours, where t is a defined time point after AFQ056 administration [mass x time / volume] normalized for dose
    End point type
    Primary
    End point timeframe
    Over 12 hours post dose on Day 1 of Treatment Period 1
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was planned for this primary outcome measure.
    End point values
    Cohort 1-Treatment Period 1 Cohort 2-Treatment Period 1
    Number of subjects analysed
    11
    9
    Units: h*ng/mL/mg
        geometric mean (confidence interval 90%)
    11.2 (8.32 to 15)
    16.4 (13.3 to 20.3)
    No statistical analyses for this end point

    Primary: Cmax After a Single Dose of AFQ056

    Close Top of page
    End point title
    Cmax After a Single Dose of AFQ056 [3]
    End point description
    The observed maximum plasma concentration following AFQ056 administration [mass / volume]
    End point type
    Primary
    End point timeframe
    Over 24 hours post dose on Day 1 of Treatment Period 1
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was planned for this primary outcome measure.
    End point values
    Cohort 1-Treatment Period 1 Cohort 2-Treatment Period 1
    Number of subjects analysed
    12
    9
    Units: ng/mL
        geometric mean (confidence interval 90%)
    43.1 (31.3 to 59.5)
    70 (55.7 to 88.1)
    No statistical analyses for this end point

    Primary: AUC0-12h After a Single Dose of AFQ056

    Close Top of page
    End point title
    AUC0-12h After a Single Dose of AFQ056 [4]
    End point description
    The AUC from time 0 to t= 12 hours, where t is a defined time point after AFQ056 administration [mass x time / volume]
    End point type
    Primary
    End point timeframe
    Over 24 hours post dose on Day 1 of Treatment Period 1
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was planned for this primary outcome measure.
    End point values
    Cohort 1-Treatment Period 1 Cohort 2-Treatment Period 1
    Number of subjects analysed
    11
    9
    Units: h*ng/mL
        geometric mean (confidence interval 90%)
    168 (125 to 225)
    246 (199 to 304)
    No statistical analyses for this end point

    Primary: Dose-normalized Cmax of AFQ056 at Steady State

    Close Top of page
    End point title
    Dose-normalized Cmax of AFQ056 at Steady State [5]
    End point description
    The observed maximum plasma concentration following AFQ056 administration [mass / volume] normalized for dose after multiple doses
    End point type
    Primary
    End point timeframe
    Over 24 hours post dose on Day 7 or 8 of Treatment Period 2 for Cohort 1 and 2, respectively
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was planned for this primary outcome measure.
    End point values
    Cohort 1-Treatment Period 2 Cohort 2-Treatment Period 2
    Number of subjects analysed
    12
    9
    Units: ng/mL/mg
        geometric mean (confidence interval 90%)
    3.65 (2.84 to 4.69)
    3.77 (2.36 to 6.01)
    No statistical analyses for this end point

    Primary: Dose-normalized AUC0-12h of AFQ056 at Steady State

    Close Top of page
    End point title
    Dose-normalized AUC0-12h of AFQ056 at Steady State [6]
    End point description
    The AUC from time 0 to t= 12 hours, where t is a defined time point after AFQ056 administration [mass x time / volume] normalized for dose after multiple doses
    End point type
    Primary
    End point timeframe
    Over 24 hours post dose on Day 7 or 8 of Treatment Period 2 for Cohort 1 and 2, respectively
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was planned for this primary outcome measure.
    End point values
    Cohort 1-Treatment Period 2 Cohort 2-Treatment Period 2
    Number of subjects analysed
    5
    4
    Units: h*ng/mL/mg
        geometric mean (confidence interval 90%)
    13.1 (10.8 to 15.9)
    19.5 (11.1 to 34.2)
    No statistical analyses for this end point

    Secondary: Number of Patients With Clinically Significant Abnormalities in Laboratory Values

    Close Top of page
    End point title
    Number of Patients With Clinically Significant Abnormalities in Laboratory Values
    End point description
    End point type
    Secondary
    End point timeframe
    Screening: once anytime between Day -30 and Day -1; once anytime between 24-72 hours after Day 7 or 8 for Cohort 1 and 2, respectively
    End point values
    Cohort 1-Treatment Period 2 Cohort 2-Treatment Period 2
    Number of subjects analysed
    12
    9
    Units: subjects
        Hematology
    0
    0
        Blood Chemistry
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Patients With Clinically Significant Abnormalities in Vital Signs And Body Measurements

    Close Top of page
    End point title
    Number of Patients With Clinically Significant Abnormalities in Vital Signs And Body Measurements
    End point description
    End point type
    Secondary
    End point timeframe
    Screening: once anytime between Day -30 and Day -1; once anytime between 24-72 hours after Day 7 or 8 for Cohort 1 and 2, respectively
    End point values
    Cohort 1-Treatment Period 2 Cohort 2-Treatment Period 2
    Number of subjects analysed
    12
    9
    Units: subjects
        Body Height
    0
    0
        Body Weight
    0
    0
        Body Temperature
    0
    0
        Blood Pressure/Pulse Rate
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Patients With Clinically Significant Abnormalities in Electrocardiogram Results

    Close Top of page
    End point title
    Number of Patients With Clinically Significant Abnormalities in Electrocardiogram Results
    End point description
    End point type
    Secondary
    End point timeframe
    Screening: once anytime between Day -30 and Day -1; once anytime between 24-72 hours after Day 7 or 8 for Cohort 1 and 2, respectively
    End point values
    Cohort 1-Treatment Period 2 Cohort 2-Treatment Period 2
    Number of subjects analysed
    12
    9
    Units: subjects
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Patients With Clinically Significant Abnormalities Upon Neurological Examination

    Close Top of page
    End point title
    Number of Patients With Clinically Significant Abnormalities Upon Neurological Examination
    End point description
    End point type
    Secondary
    End point timeframe
    Screening: once anytime between Day -30 and Day -1; once on Day 7 or 8 for Cohort 1 and 2, respectively
    End point values
    Cohort 1-Treatment Period 2 Cohort 2-Treatment Period 2
    Number of subjects analysed
    12
    9
    Units: subjects
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Patients With Adverse Events

    Close Top of page
    End point title
    Number of Patients With Adverse Events
    End point description
    End point type
    Secondary
    End point timeframe
    During the study (total of approximately 32 days) and 3 days after study completion
    End point values
    Cohort 1-Treatment Period 2 Cohort 2-Treatment Period 2
    Number of subjects analysed
    12
    9
    Units: subjects
        Serious adverse events
    0
    0
        Non-serious adverse events
    9
    6
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Serious Adverse Events are monitored from date of First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All other adverse events are monitored from First Patient First Treatment until Last Patient Last Visit.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    15.1
    Reporting groups
    Reporting group title
    Cohort 1 Period 1 15mg AFQ056
    Reporting group description
    Cohort 1 Period 1 15mg AFQ056

    Reporting group title
    Cohort 1 Period 2 50mg AFQ056
    Reporting group description
    Cohort 1 Period 2 50mg AFQ056

    Reporting group title
    Cohort 1 Period 2 60mg AFQ056
    Reporting group description
    Cohort 1 Period 2 60mg AFQ056

    Reporting group title
    Cohort 1 Period 2 20mg AFQ056
    Reporting group description
    Cohort 1 Period 2 20mg AFQ056

    Reporting group title
    Cohort 1 Period 2 100mg AFQ056
    Reporting group description
    Cohort 1 Period 2 100mg AFQ056

    Reporting group title
    Cohort 1 Total
    Reporting group description
    Cohort 1 Total

    Reporting group title
    Cohort 2 Period 2 20mg AFQ056
    Reporting group description
    Cohort 2 Period 2 20mg AFQ056

    Reporting group title
    Cohort 2 Period 2 15mg AFQ056
    Reporting group description
    Cohort 2 Period 2 15mg AFQ056

    Reporting group title
    Cohort 2 Period 1 15mg AFQ056
    Reporting group description
    Cohort 2 Period 1 15mg AFQ056

    Reporting group title
    Cohort 2 Period 2 50mg AFQ056
    Reporting group description
    Cohort 2 Period 2 50mg AFQ056

    Reporting group title
    Cohort 2 Period 2 100mg AFQ056
    Reporting group description
    Cohort 2 Period 2 100mg AFQ056

    Reporting group title
    Cohort 2 Total
    Reporting group description
    Cohort 2 Total

    Serious adverse events
    Cohort 1 Period 1 15mg AFQ056 Cohort 1 Period 2 50mg AFQ056 Cohort 1 Period 2 60mg AFQ056 Cohort 1 Period 2 20mg AFQ056 Cohort 1 Period 2 100mg AFQ056 Cohort 1 Total Cohort 2 Period 2 20mg AFQ056 Cohort 2 Period 2 15mg AFQ056 Cohort 2 Period 1 15mg AFQ056 Cohort 2 Period 2 50mg AFQ056 Cohort 2 Period 2 100mg AFQ056 Cohort 2 Total
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Cohort 1 Period 1 15mg AFQ056 Cohort 1 Period 2 50mg AFQ056 Cohort 1 Period 2 60mg AFQ056 Cohort 1 Period 2 20mg AFQ056 Cohort 1 Period 2 100mg AFQ056 Cohort 1 Total Cohort 2 Period 2 20mg AFQ056 Cohort 2 Period 2 15mg AFQ056 Cohort 2 Period 1 15mg AFQ056 Cohort 2 Period 2 50mg AFQ056 Cohort 2 Period 2 100mg AFQ056 Cohort 2 Total
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    4 / 12 (33.33%)
    3 / 3 (100.00%)
    1 / 1 (100.00%)
    1 / 1 (100.00%)
    4 / 6 (66.67%)
    9 / 12 (75.00%)
    1 / 1 (100.00%)
    1 / 1 (100.00%)
    2 / 9 (22.22%)
    3 / 4 (75.00%)
    1 / 1 (100.00%)
    6 / 9 (66.67%)
    Vascular disorders
    Hot flush
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Nervous system disorders
    Coordination abnormal
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Dizziness
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    2 / 6 (33.33%)
    2 / 12 (16.67%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    3
    3
    0
    0
    0
    0
    0
    0
    Dyskinesia
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 3 (33.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Headache
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    2
    0
    0
    0
    0
    0
    0
    Hypersomnia
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Psychomotor hyperactivity
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 3 (33.33%)
    0 / 1 (0.00%)
    1 / 1 (100.00%)
    0 / 6 (0.00%)
    2 / 12 (16.67%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    3
    0
    3
    0
    6
    0
    0
    0
    0
    0
    0
    Somnolence
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    General disorders and administration site conditions
    Feeling hot
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Eye disorders
    Eye pain
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Mydriasis
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    2
    0
    0
    0
    0
    0
    0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 3 (33.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    2 / 12 (16.67%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    Food poisoning
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Vomiting
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 3 (66.67%)
    0 / 1 (0.00%)
    1 / 1 (100.00%)
    3 / 6 (50.00%)
    6 / 12 (50.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    2
    0
    1
    3
    6
    0
    0
    0
    0
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Nasal congestion
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    1 / 1 (100.00%)
    1 / 9 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Oropharyngeal pain
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Hyperhidrosis
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Rash
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    1 / 1 (100.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    Swelling face
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Urticaria
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    1 / 1 (100.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    Psychiatric disorders
    Anticipatory anxiety
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 6 (16.67%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    2
    0
    0
    0
    0
    0
    0
    Anxiety
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    1 / 1 (100.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Initial insomnia
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    1 / 1 (100.00%)
    1 / 6 (16.67%)
    2 / 12 (16.67%)
    1 / 1 (100.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
         occurrences all number
    0
    0
    0
    1
    1
    2
    1
    0
    0
    0
    0
    1
    Insomnia
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    2 / 4 (50.00%)
    0 / 1 (0.00%)
    2 / 9 (22.22%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    2
    Renal and urinary disorders
    Pollakiuria
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 3 (33.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Infections and infestations
    Gastrointestinal viral infection
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    0 / 1 (0.00%)
    1 / 1 (100.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    1
    Hordeolum
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Infected bites
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    1
    Nasopharyngitis
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 3 (33.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    1 / 12 (8.33%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    0 / 9 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Pharyngitis
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 3 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    0 / 6 (0.00%)
    0 / 12 (0.00%)
    0 / 1 (0.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
    1 / 9 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    23 Nov 2011
    This amendment introduced the following changes: The additional safety monitoring of study patients on days 2-6 (period 2) in case when the study medication is administered at patient’s home by the patient’s caregiver. For these days a daily telephone call was recommended to monitor for the potential AEs and safety issues. Initially planned two visits per day in the study center for the study drug administration were considered too stressful for the patients and considering the safety profile of AFQ056 it was judged that the daily telephone call was an appropriate measure to monitor for the safety of the study patients. In addition the meal restriction section was rewritten to provide more flexibility to the patients regarding the meal times on period 2. Further, the b.i.d. dose was introduced for day 1, period 2 (instead of single dose). Originally, it was planned to assess the single-dose pharmacokinetics from 0-24h post dosing. As this was no longer planned to be assessed, the b.i.d. dosing regimen was applied over the entire period 2 (i.e. from day 1-7). This was to ensure a consistent dosing regimen and it would allow for a more appropriate tolerability assessment after an overnight stay of the patients at the site. This assessment was done in the morning of day 2 before patients leave the study site.
    24 Feb 2012
    This amendment introduced the following changes: In order to further characterize any potential modification of attention after AFQ056 administration to children with FXS, it was decided to perform mental age-appropriate subtests of the Test of Everyday Attention in Childhood (TEA-Ch). In addition, TEA-Ch was included in order to comply with a request by the European Medicines Agency (EMA) received in the course of the PIP review. To minimize the burden for the patients, TEA-Ch subtests were only performed in the multiple-dosing period 2, as after administration of a considerably low, single dose of AFQ056 in period 1 (15 mg), no meaningful modification of behavior was expected. Further, these subtest would only be applied in cohort 1 (5-11 year-old patients), since it was not considered feasible to perform these tests in cohort 2 (3-4 year-old patients) given that these tests have been validated for children ≥6 years of age. The tests were done at baseline, 24 h after first dosing in period 2 and at final visit if possible based on the capabilities of study patients (as judged by Investigator).
    11 May 2012
    This amendment introduced the following changes: In the original study protocol, (a) sequential dosing within cohort 1 beginning with the older (8 to 11 years) followed by the younger patients (5 to 7 years) and (b) an equal number of 5 to 7 year-old and 8-11 year-old patients in cohort 1 was required. This had been implemented due to the absence of any PK data in the pediatric population of FXS patients younger than 12 years. As per this amendment sequential age-dependent dosing as well as an equal age distribution of patients aged 8-11 and 5-7yrs will no longer be required. This was to minimize the burden to the families/caregivers of the FXS patients, since there were often siblings interested in study participation. Therefore, it was expected to improve the recruitment in this study. This amendment would not affect the validity of the statistical analysis as this has originally been planned to be done on the entire cohort 1 without age discrimination. It was also not expected to affect the safety and tolerability of AFQ056 in this study population of pediatric FXS patients.
    11 Jul 2012
    This amendment introduced the following changes: After a review of Amendment 03, FDA stated via e-mail dated June 29, 2012, that the removal of an equal age distribution in cohort 1 is not acceptable. It was stated that an equal number of 5 to 7 year-old and 8 to11 year-old patients was necessary for the PK trial to be informative given the expected difference in ontogeny among these age groups. Therefore, the requirement for an equal number of six patients aged 5 to 7 years and another six patients aged 8-11 years was re-introduced in this protocol amendment 04.
    22 Mar 2013
    This amendment introduced the following changes: This study evaluated the pharmacokinetics as well as safety and tolerability of AFQ056 in pediatric patients with FXS aged 5-11 years (cohort 1) and 3-4 years (cohort 2). As of 22- Mar-2013, cohort 1, consisting of 12 children with FXS, has completed the study. This was followed by a pre-planned interim analysis to decide upon continuation of this study with cohort 2. Based on the data obtained in cohort 1, it has been decided to continue with cohort 2 and to implement three key changes to the protocol * An up-titration scheme with a starting dose of 25mg b.i.d. and daily increments of 25mg up to the assigned target dose will be applied in period 2, cohort 2. This up-titration aims at reducing the incidence of AEs (e.g. vomiting) that are considered to be first-dose related, as these occurred primarily on the first day of the multiple-dosing period 2 in cohort 1. * As a consequence of the up-titration, the duration of the treatment in period 2, cohort 2 was extended from 7 to 8 days to assure that the steady state at the target dose is reached (the steady state is known to reach between 48h to 96 h for AFQ056) when the PK samples for AFQ056 measurements are collected. * The sample size required for cohort 2 has been re-evaluated based on the PK data obtained in cohort 1. This has been done in order to minimize the number of patients exposed which appears particularly important given the low age of patients in cohort 2 (3-4 years).

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 11:30:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA